Ivonescimab improves survival in advanced non-small cell lung cancer
1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade ...
Tag: non-small cell lung cancer
Amivantumab plus lazertinib improves survival in EGFR-mutated advanced NSCLC
1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung ...
Perioperative pembrolizumab improves survival in resectable early-stage non-small cell lung cancer
1. 36-month overall survival and median event-free survival were significantly greater in the pembrolizumab group compared to control. 2. Grade ...
#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Amivantamab plus Lazertinib Improves Outcomes in Previously Untreated EGFR-Mutated Advanced NSCLC
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract Osimertinib significantly improved progression-free survival in patients with unresectable stage III non-small cell lung cancer
Click to read the study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Osimertinib after Chemoradiotherapy Increases Survival in Stage III EGFR-Mutated NSCLC
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Alectinib Improves Disease-Free Survival in ALK-Positive Non-Small-Cell Lung Cancer Compared to Platinum-Based Chemotherapy
Click here to read this study in The New England Journal of Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No ...
#VisualAbstract: Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed ...
#VisualAbstract: Perioperative Toripalimab Plus Chemotherapy Improves Event-Free Survival in Patients With Resectable Non–Small-Cell Lung Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...